CAC
MRSN

Cowen and Company’s Mersana Therapeutics MRSN Stock Holding History

Cowen and Company’s Portfolio MRSN Stock Details MRSN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-1,176
Closed -$399K – 663
2021
Q2 		$399K Buy
1,176
+332
+39% +$126K 0.02% 207
2021
Q1 		$341K Buy
+844
New +$409K 0.02% 224

Other funds holding MRSN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $178M AUM 118.43% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Cowen and Company's MRSN Position: Q3 2021 in Review

Cowen and Company sold out of Mersana Therapeutics (MRSN) in Q3 2021, closing a stake of 1,176 shares — an estimated $399K sold.

Cowen and Company first reported a position in MRSN in Q1 2021 and held it in 2 quarters. The position peaked at $399K in Q2 2021. 109 funds tracked by Wall St. Rank hold MRSN as of Q3 2021.

  • Cowen and Company reported no remaining Mersana Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Cowen and Company sold 1,176 Mersana Therapeutics shares in Q3 2021, an estimated $399K.
  • Cowen and Company first reported a position in Mersana Therapeutics in Q1 2021 and held it in 2 quarters.
  • Cowen and Company's Mersana Therapeutics position peaked at $399K in Q2 2021.
  • 109 funds tracked by Wall St. Rank held Mersana Therapeutics as of Q3 2021.

Based on Cowen and Company's 13F filing for Q3 2021, filed 12 Nov 2021.